Skip to main content
TipRanks
Go Ultimate75% OFF

Identa (IDTA) AI Stock Analysis

11 Followers
IDTA

Identa

(Other OTC:IDTA)

Select Model
Rating:78Outperform
Price Target:$0.26â–²(13.91% Upside)
Action:upgraded
Date:08/20/26

IDTA's solid score of 78 is primarily driven by its highly attractive valuation and robust technical momentum, with shares trading well above key moving averages. The company's underlying fundamentals provide reliable support, featuring a significantly deleveraged balance sheet and recovering profitability, though historical top-line and cash flow volatility remain a minor tempering factor.

Positive Factors
Improved profitability and revenue growthThe recent combination of revenue growth and healthy gross, operating, and net margins indicates improved operating performance. If maintained, stronger profitability can support internal reinvestment and provide a more durable earnings base over the next several quarters.
Negative Factors
Uneven operating cash-flow reliabilityThe history of negative operating cash flow and weaker conversion in a recent period makes cash generation less dependable than the latest positive result suggests. This inconsistency can constrain internally funded growth and increase reliance on balance-sheet resources during weaker operating periods.

Identa (IDTA) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%IDTA-11.54%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$930.49K
Dividend Yield
―
Average Volume (3M)
3,326
Price to Earnings (P/E)
6.5
Beta (1Y)
-1.56
Revenue Growth
57.25%
EPS Growth
―
Country
US
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Medical - Specialties

Identa Business Overview & Revenue Model

Company Description

IDenta Corp. operates as a detection and forensic science company. The company offers drug testing kits, explosives testing kits, aero chamber sniffer, forensic, urine drug testing, and saliva drug testing products. It provides its solutions to law e...

How the Company Makes Money

null

Identa Financial Statement Overview

Summary

IDTA exhibits a strong financial foundation highlighted by active debt reduction and a fortified balance sheet. While revenue and cash flow have seen historical volatility, recent trailing-twelve-month results show promising stabilization with expanding net profit margins and positive cash generation.

Income Statement

72Positive

Balance Sheet

86Very Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.86M1.34M1.46M1.05M1.34M1.39M
Gross Profit958.46K686.57K756.46K662.98K983.39K1.02M
EBITDA254.66K128.96K328.40K57.13K199.56K135.57K
Net Income141.05K99.04K258.34K14.64K162.71K69.18K
Balance Sheet
Total Assets2.38M1.92M1.66M1.53M1.56M1.23M
Cash, Cash Equivalents and Short-Term Investments669.76K379.42K735.95K264.29K368.90K347.15K
Total Debt661.18K645.20K640.23K785.37K820.28K511.63K
Total Liabilities1.08M1.04M921.01K1.01M1.10M799.32K
Stockholders Equity1.30M879.16K742.31K516.12K459.63K430.01K
Cash Flow
Free Cash Flow253.53K40.28K555.85K-151.97K61.56K-221.97K
Operating Cash Flow284.25K56.94K561.89K-137.63K94.31K-88.95K
Investing Cash Flow-87.01K-48.05K-260.40K-8,154-8,611-133.02K
Financing Cash Flow276.22K-43.78K-151.47K-23.53K-63.95K28.02K

Identa Technical Analysis

Technical Analysis SentimentNegative
Last Price0.23

Price Trends

50DMA0.32Negative
100DMA0.29Negative
200DMA0.25Negative

Market Momentum

MACD-0.03Positive
RSI17.59Positive
STOCH6.67Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDTA, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.32, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 17.59 is Positive, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDTA.

Identa Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IDTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IDTAIDTA78Outperform$930.49K6.4614.16%―57.25%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BIAFBIAF43Neutral$3.51M-0.04-331.02%―-18.47%87.82%
NDRANDRA42Neutral$5.88M-0.77-150.38%――60.87%
INBSINBS41Neutral$5.11M-0.23-146.09%―36.55%60.09%
BNBXBNBX38Underperform$470.99K-0.00-337.10%―-27.39%99.29%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%IDTABNBXNDRAINBSBIAFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IDTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IDTAIdenta Corp0.23-0.03-11.54%
BNBXBnb Plus Corp.0.08-2.42-96.80%
NDRAEndra Life Sciences4.04-1.60-28.46%
INBSIntelligent Bio Solutions Inc.1.54-4.88-76.01%
BIAFbioAffinity Technologies, Inc.2.15-18.55-89.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026